I believe the gist of it is: FDA is willing to accept new potency data generated to pave the way for FDA to consider pH 3 trial MAB-GVHD001 gor paediatrics as adequate study. I think (a) a few months is quite a good time frame for a potentially significant outcome.
Re adults, a 12 month controlled single arm is also quite a reasonable outcome and given the data and evidence already, that should be a matter of ticking the box ... something FDA likes.
So, much better than we could have potentially ntcipated.
Ann: Mesoblast Type A Meeting with FDA, page-8
-
- There are more pages in this discussion • 567 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.010(1.02%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 95.5¢ | $6.248M | 6.438M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 116040 | 7 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |